Navigation Links
Sanovas Expands Headquarters and Opens Manufacturing Site
Date:1/24/2012

SAUSALITO, Calif., Jan. 24, 2012 /PRNewswire/ -- Sanovas, a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases, announced today that it has expanded its corporate headquarters and opened a manufacturing site in Sausalito, Calif. The facility will initially manufacture critical components of Sanovas' technology ahead of filing for U.S. Food and Drug Administration approval, and would ultimately serve to produce Sanovas' commercial products.

"Sanovas' headquarters is a natural choice for our manufacturing site, as it allows us to maintain the highest level of quality control over the most proprietary components of our technology platform," CEO Larry Gerrans said. "These facilities will provide us with the ability to attract the very best talent from within the life sciences community right here in the Bay Area."

Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and understand previously inaccessible areas of the body, enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. Developed by the pioneers in the field of minimally invasive devices, this intelligent micro-surgical technology platform utilizes the world's smallest surgical camera to visualize and treat difficult-to-reach areas of the body. The camera is connected to the end of a steerable catheter that is further used to deliver additional tools for collecting tissue samples, analyzing and removing tumors and delivering drug and immune therapies to targeted locations within the deepest reaches of the body.

Sanovas plans to file a 510(K) submission with the FDA within the first half of 2012 for approval of its technology, and if approved, would begin full-scale manufacturing by the end of the year. Initially, Sanovas intends to market its micro-surgical tools for the treatment of lung cancer and pulmonary disease. Lung cancer is the leading cause of cancer death among men and women worldwide, and nearly 400,000 people in the United States die from lung disease each year, according to the American Lung Association.

"With nearly one in seven Americans currently suffering from a chronic pulmonary disease and another 96 million at risk, there is an urgent humanitarian need for these next-generation solutions," Gerrans said.

About Sanovas

Sanovas, Inc., based in Sausalito, Calif., is a leading developer of innovative micro-surgical devices for diagnosing and treating cancer and chronic diseases. Sanovas' micro-surgical technology platform is designed to give surgeons the ability to access and visualize previously inaccessible areas of the body; enabling them to diagnose, treat and deliver drug and immune therapies to small diameter anatomy in entirely new ways. The company plans to commercialize its technology platform, which will initially address the unmet needs in lung cancer and pulmonary disease, in 2012. Privately held Sanovas was founded by the pioneers in minimally invasive surgery. The company has more than 25 multi-national patents pending.

Media Contacts:                                        
Racepoint Group
For Sanovas
Marla Kertzman, 415-694-6701


'/>"/>
SOURCE Sanovas
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanovas CEO Larry Gerrans Featured Speaker at AdvaMed 2011
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Cellectar Expands Clinical Management Team
5. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. PAREXEL Expands Global Clinical Pharmacology Capabilities
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ORLANDO, Fla. , July 17, 2017  MedX ... - branded medical testing, strengthening and rehabilitation equipment, today ... Back Machine Program. MedX is considered the gold standard ... world leader in specialized medical strengthening equipment. ... into a lease with the physician or practice who ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company ... agreement with generic companies to resolve pending patent litigation in ... Virginia regarding the Cialis ® (tadalafil) ... on April 26, 2020. As part of the agreement, Cialis ... September 27, 2018. "The unit dose patent for ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern Georgie ... Foundation in a community wide charity event with the goal of bringing in support ... local woman who lives with epilepsy, recently launched a charity campaign of her own ...
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson University , ... was awarded a $300,000 grant from The Pew Center for Arts & Heritage ... and the recognition of one’s own limits among health professions students. , ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) ... of life a decade after surgery, though activity levels decline over time. The ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
Breaking Medicine News(10 mins):